Base de dados : MEDLINE
Pesquisa : C05.651.742 [Categoria DeCS]
Referências encontradas : 2278 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 228 ir para página                         

  1 / 2278 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28905861
[Au] Autor:Dejaco C; Brouwer E; Mason JC; Buttgereit F; Matteson EL; Dasgupta B
[Ad] Endereço:Department of Rheumatology and Immunology, Medical University Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
[Ti] Título:Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.
[So] Source:Nat Rev Rheumatol;13(10):578-592, 2017 Oct.
[Is] ISSN:1759-4804
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The fields of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) have advanced rapidly, resulting in a new understanding of these diseases. Fast-track strategies and improved awareness programmes that prevent irreversible sight loss through early diagnosis and treatment are a notable advance. Ultrasonography and other imaging techniques have been introduced into routine clinical practice and there have been promising reports on the efficacy of biologic agents, particularly IL-6 antagonists such as tocilizumab, in treating these conditions. Along with these developments, which should improve outcomes in patients with GCA and PMR, new questions and unmet needs have emerged; future research should address which pathogenetic mechanisms contribute to the different phases and clinical phenotypes of GCA, what role imaging has in the early diagnosis and monitoring of GCA and PMR, and in which patients and phases of these diseases novel biologic drugs should be used. This article discusses the implications of recent developments in our understanding of GCA and PMR, as well as the unmet needs concerning epidemiology, pathogenesis, imaging and treatment of these diseases.
[Mh] Termos MeSH primário: Arterite de Células Gigantes/diagnóstico por imagem
Arterite de Células Gigantes/tratamento farmacológico
Polimialgia Reumática/diagnóstico por imagem
Polimialgia Reumática/tratamento farmacológico
[Mh] Termos MeSH secundário: Anticorpos Monoclonais Humanizados/uso terapêutico
Ensaios Clínicos como Assunto
Diagnóstico Precoce
Arterite de Células Gigantes/epidemiologia
Seres Humanos
Polimialgia Reumática/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); I031V2H011 (tocilizumab)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE
[do] DOI:10.1038/nrrheum.2017.142


  2 / 2278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28658131
[Au] Autor:Emamifar A; Hess S; Gerke O; Hermann AP; Laustrup H; Hansen PS; Thye-Rønn P; Marcussen N; Svendstrup F; Gildberg-Mortensen R; Bang JC; Farahani ZA; Chrysidis S; Toftegaard P; Andreasen RA; le Greves S; Andersen HR; Olsen RN; Hansen IMJ
[Ad] Endereço:aDepartment of Rheumatology, Odense University Hospital, Svendborg Hospital, Svendborg bFaculty of Health Sciences, University of Southern Denmark cDepartment of Nuclear Medicine, Odense University Hospital, Odense dDepartment of Radiology and Nuclear Medicine, Hospital Southwest Jutland, Esbjerg eCentre of Health Economics Research, University of Southern Denmark fDepartment of Endocrinology gDepartment of Rheumatology, Odense University Hospital, Odense hDiagnostic center, Odense University Hospital, Svendborg Hospital, Svendborg iDepartment of Pathology, Odense University Hospital, Odense jDepartment of Ear Nose Throat Surgery kDepartment of Radiology, Odense University Hospital, Svendborg Hospital, Svendborg lDepartment of Rheumatology, Hospital Southwest Jutland, Esbjerg mPatient Research Partner, Department of Rheumatology, Odense University Hospital, Svendborg Hospital, Svendborg, Denmark.
[Ti] Título:Polymyalgia rheumatica and giant cell arteritis-three challenges-consequences of the vasculitis process, osteoporosis, and malignancy: A prospective cohort study protocol.
[So] Source:Medicine (Baltimore);96(26):e7297, 2017 Jun.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are common inflammatory conditions. The diagnosis of PMR/GCA poses many challenges since there are no specific diagnostic tests. Recent literature emphasizes the ability of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to assess global disease activity in inflammatory diseases. 18F-FDG PET/CT may lead to the diagnosis at an earlier stage than conventional imaging and may also assess response to therapy. With respect to the management of PMR/GCA, there are 3 significant areas of concern as follows: vasculitis process/vascular stiffness, malignancy, and osteoporosis. METHODS AND ANALYSIS: All patients with suspected PMR/GCR referred to the Rheumatology section of Medicine Department at Svendborg Hospital, Denmark. The 4 separate studies in the current protocol focus on: the association of clinical picture of PMR/GCA with PET findings; the validity of 18F-FDG PET/CT scan for diagnosis of PMR/GCA compared with temporal artery biopsy; the prevalence of newly diagnosed malignancies in patients with PMR/GCA, or PMR-like syndrome, with the focus on diagnostic accuracy of 18F-FDG PET/CT scan compared with conventional workup (ie, chest X-ray/abdominal ultrasound); and the impact of disease process, and also steroid treatment on bone mineral density, body composition, and vasculitis/vascular stiffness in PMR/GCA patients. ETHICS AND DISSEMINATION: The study has been approved by the Regional Ethics Committee of the Region of Southern Denmark (identification number: S-20160098) and Danish Data Protection Agency (J.nr 16/40522). Results of the study will be disseminated via publications in peer-reviewed journals, and presentation at national and international conferences.
[Mh] Termos MeSH primário: Arterite de Células Gigantes/diagnóstico
Arterite de Células Gigantes/tratamento farmacológico
Polimialgia Reumática/diagnóstico
Polimialgia Reumática/tratamento farmacológico
Prednisolona/uso terapêutico
Esteroides/uso terapêutico
[Mh] Termos MeSH secundário: Biópsia
Dinamarca
Fluordesoxiglucose F18
Arterite de Células Gigantes/complicações
Arterite de Células Gigantes/fisiopatologia
Seres Humanos
Meia-Idade
Neoplasias/complicações
Neoplasias/epidemiologia
Osteoporose/induzido quimicamente
Osteoporose/fisiopatologia
Seleção de Pacientes
Polimialgia Reumática/complicações
Polimialgia Reumática/fisiopatologia
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
Prednisolona/efeitos adversos
Prevalência
Compostos Radiofarmacêuticos
Método Simples-Cego
Esteroides/efeitos adversos
Artérias Temporais/patologia
Vasculite/fisiopatologia
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Radiopharmaceuticals); 0 (Steroids); 0Z5B2CJX4D (Fluorodeoxyglucose F18); 9PHQ9Y1OLM (Prednisolone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170718
[Lr] Data última revisão:
170718
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007297


  3 / 2278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28600350
[Au] Autor:Belkhir R; Burel SL; Dunogeant L; Marabelle A; Hollebecque A; Besse B; Leary A; Voisin AL; Pontoizeau C; Coutte L; Pertuiset E; Mouterde G; Fain O; Lambotte O; Mariette X
[Ad] Endereço:Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, France.
[Ti] Título:Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
[So] Source:Ann Rheum Dis;76(10):1747-1750, 2017 Oct.
[Is] ISSN:1468-2060
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 (PD-1) have demonstrated improved survival for multiple cancers. However, these new drug classes have led to increased immune-related adverse events (IrAE). Rheumatic IrAEs have not been well described in clinical trials. We report here cases of rheumatoid arthritis (RA) and polymyalgia rheumatica (PMR) occurring after ICI treatment. METHODS: This was a retrospective study of patients receiving an ICI in whom symptoms of arthritis or arthralgia developed and revealed a diagnosis of RA or PMR. RESULTS: In 10 patients who received ICI therapy (all anti-PD-1 or anti-PDL1 antibodies), RA or PMR developed at a median of 1 month (1 to 9) after exposure. No patient had pre-existing rheumatic or autoimmune disease. RA developed in six patients; all six were positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies and four for rheumatoid factor. Anti-CCP antibodies were detected in two out of three patients tested before immunotherapy. Disease-modifying antirheumatic drugs were needed for three patients; the three others received corticosteroids or non-steroid anti-inflammatory drugs. PMR was diagnosed in four patients, all responded to corticosteroids. Despite these IrAEs, immunotherapy was pursued for all but one patient until cancer progression. CONCLUSIONS: This is the first description of RA occurring after ICI therapy for cancer. PMR can also occur after ICI, particularly after anti-PD-1 therapy. All cases responded to corticosteroids or with immunosuppressive therapy. Collaboration between rheumatologists and oncologists is crucial and could lead to better recognition and care of these patients.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/efeitos adversos
Anticorpos Monoclonais/efeitos adversos
Antineoplásicos/efeitos adversos
Artrite Reumatoide/induzido quimicamente
Polimialgia Reumática/induzido quimicamente
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Anticorpos/sangue
Artrite Reumatoide/sangue
Artrite Reumatoide/tratamento farmacológico
Antígeno B7-H1/antagonistas & inibidores
Antígeno CTLA-4/antagonistas & inibidores
Feminino
Seres Humanos
Ipilimumab
Masculino
Meia-Idade
Peptídeos Cíclicos/imunologia
Polimialgia Reumática/sangue
Polimialgia Reumática/tratamento farmacológico
Receptor de Morte Celular Programada 1/antagonistas & inibidores
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies); 0 (Antibodies, Monoclonal); 0 (Antibodies, Monoclonal, Humanized); 0 (Antineoplastic Agents); 0 (B7-H1 Antigen); 0 (CTLA-4 Antigen); 0 (Ipilimumab); 0 (Peptides, Cyclic); 0 (Programmed Cell Death 1 Receptor); 0 (cyclic citrullinated peptide); 31YO63LBSN (nivolumab); DPT0O3T46P (pembrolizumab)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170611
[St] Status:MEDLINE
[do] DOI:10.1136/annrheumdis-2017-211216


  4 / 2278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28508663
[Au] Autor:Rehak Z; Sprlakova-Pukova A; Kazda T; Fojtik Z; Vargova L; Nemec P
[Ad] Endereço:1 Department of Nuclear Medicine and PET Center, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
[Ti] Título:F-FDG PET/CT in polymyalgia rheumatica-a pictorial review.
[So] Source:Br J Radiol;90(1076):20170198, 2017 Aug.
[Is] ISSN:1748-880X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Polymyalgia rheumatica (PMR) is one of the inflammatory rheumatic diseases that can potentially be detected by positron emission tomography/CT. High fluorine-18 fludeoxyglucose ( F-FDG) accumulation around the shoulders, sternoclavicular and hip joints are the most common pre-treatment features of patients with PMR. Another common sign is increased F-FDG uptake in extra-articular regions between columnal spinous processes, near ischial tuberosities and in the praepubic area. Some patients also present with high F-FDG uptake in main arteries, corresponding to the characteristics of giant cell arteritis. It is possible to observe a decrease or even a disappearance of F-FDG uptake after effective therapy, an event which may be useful for the monitoring of treatment as well as for detection of PMR relapse.
[Mh] Termos MeSH primário: Fluordesoxiglucose F18
Polimialgia Reumática/diagnóstico por imagem
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons/métodos
Compostos Radiofarmacêuticos
[Mh] Termos MeSH secundário: Articulação do Quadril/diagnóstico por imagem
Seres Humanos
Articulação do Ombro/diagnóstico por imagem
Articulação Esternoclavicular/diagnóstico por imagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170517
[St] Status:MEDLINE
[do] DOI:10.1259/bjr.20170198


  5 / 2278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28431111
[Au] Autor:Carvajal Alegria G; Devauchelle-Pensec V; Renaudineau Y; Saraux A; Pers JO; Cornec D
[Ad] Endereço:Rheumatology Department, CHRU Cavale Blanche.
[Ti] Título:Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica.
[So] Source:Rheumatology (Oxford);56(8):1401-1406, 2017 Aug 01.
[Is] ISSN:1462-0332
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: The aim was to study lymphocyte subsets and circulating cytokines at diagnosis of PMR and after tocilizumab monotherapy. Methods: Eighteen untreated patients with PMR were included in a prospective study and received 3-monthly tocilizumab infusions without glucocorticoids. Lymphocyte subset distribution was assessed by flow cytometry and serum cytokines were assayed by a 34-cytokine array and ELISA, at baseline and during follow-up. Baseline data were also compared with age- and sex-matched controls. Results: At baseline, total lymphocytes, T-cell subsets and NK cell counts were similar in patients and controls, but patients had significantly lower B-cell counts attributable to lower transitional, naïve and post-switch memory B-cell subsets. Circulating B-cell counts were positively correlated with the PMR activity score (PMR-AS) in untreated active patients at baseline, but subsequently increased to normal values while disease activity was controlled after tocilizumab therapy. Among serum cytokines, IL-6 showed the largest concentration difference between patients and controls, and the serum IL-6 concentration was correlated with baseline PMR-AS. The effects of tocilizumab on serum IL-6 concentration were heterogeneous, and the patients whose serum IL-6 decreased after tocilizumab therapy exhibited a significant increase in circulating B-cell counts. Conclusion: In patients with PMR, B-cell lymphopenia and abnormal B-cell subset distribution are associated with disease activity and IL-6 concentration, and both are corrected by the IL-6 antagonist tocilizumab.
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/administração & dosagem
Subpopulações de Linfócitos B/efeitos dos fármacos
Interleucina-6/sangue
Polimialgia Reumática/sangue
Polimialgia Reumática/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Estudos de Casos e Controles
Citocinas/sangue
Ensaio de Imunoadsorção Enzimática
Feminino
Citometria de Fluxo
França
Seres Humanos
Interleucina-6/antagonistas & inibidores
Masculino
Meia-Idade
Estudos Prospectivos
Índice de Gravidade de Doença
Subpopulações de Linfócitos T
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Cytokines); 0 (IL6 protein, human); 0 (Interleukin-6); I031V2H011 (tocilizumab)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170422
[St] Status:MEDLINE
[do] DOI:10.1093/rheumatology/kex169


  6 / 2278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28375837
[Au] Autor:De Lorenzi C; Rosa GM; Camellino D; Morbelli S; Dorighi U; Masoero G; Sambuceti G; Brunelli C; Cimmino MA
[Ad] Endereço:Radiology Unit, Department of Health Sciences, University of Genova, Italy.
[Ti] Título:Cardiac and aortic involvement in patients with polymyalgia rheumatica: a study with echocardiography and FDG-PET/CT.
[So] Source:Clin Exp Rheumatol;35 Suppl 103(1):224, 2017 Mar-Apr.
[Is] ISSN:0392-856X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Mh] Termos MeSH primário: Aorta/diagnóstico por imagem
Aneurisma Aórtico/diagnóstico por imagem
Insuficiência da Valva Aórtica/diagnóstico por imagem
Ecocardiografia
Fluordesoxiglucose F18/administração & dosagem
Coração/diagnóstico por imagem
Polimialgia Reumática/diagnóstico por imagem
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
Compostos Radiofarmacêuticos/administração & dosagem
[Mh] Termos MeSH secundário: Aneurisma Aórtico/etiologia
Insuficiência da Valva Aórtica/etiologia
Estudos de Casos e Controles
Seres Humanos
Polimialgia Reumática/complicações
Valor Preditivo dos Testes
Prognóstico
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170923
[Lr] Data última revisão:
170923
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE


  7 / 2278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28324118
[Au] Autor:Park J; Sung DH
[Ad] Endereço:Department of Rehabilitation Medicine, Gangnam Severance Hospital, Rehabilitation Institute of Neuromuscular Disease, Yonsei University College of Medicine, Seoul, Republic of Korea.
[Ti] Título:Early onset polymyalgia rheumatica: two rare cases under age of 50.
[So] Source:Skeletal Radiol;46(6):837-840, 2017 Jun.
[Is] ISSN:1432-2161
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Polymyalgia rheumatica (PMR) is almost an exclusive disease of adults over the age of 50, and only a few cases have been reported. Two 46-year-old females visited our locomotor pain clinic with multiple joint pain with increased acute phase reactants. Rheumatologic markers, and HLA-B27 were checked. Serum protein electrophoresis and serum immunofixation electrophoresis, imaging studies including plane image, sonography, and magnetic resonance image was done. F-Fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) showed characteristic findings of PMR, without evidences of sacroiliitis. Since PMR can develop in mid 40s, a high index of suspicion is necessary in younger patients presenting the bilateral pain in shoulders, hips, and back, with elevated acute phase reactants. Furthermore, in addition to the previous case reports, FDG-PET/CT is helpful in making early differential diagnosis of PMR in patients under the age of 50. Here we present two cases of PMR onset in the mid-40s emphasizing the importance of diagnostic imaging for early differential diagnosis in PMR.
[Mh] Termos MeSH primário: Fluordesoxiglucose F18
Polimialgia Reumática/diagnóstico por imagem
Tomografia Computadorizada com Tomografia por Emissão de Pósitrons
[Mh] Termos MeSH secundário: Anti-Inflamatórios/uso terapêutico
Artralgia/diagnóstico por imagem
Artralgia/etiologia
Diagnóstico Diferencial
Feminino
Seres Humanos
Articulações/diagnóstico por imagem
Meia-Idade
Polimialgia Reumática/complicações
Polimialgia Reumática/diagnóstico
Polimialgia Reumática/tratamento farmacológico
Prednisolona/uso terapêutico
Compostos Radiofarmacêuticos
Imagem Corporal Total/métodos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Radiopharmaceuticals); 0Z5B2CJX4D (Fluorodeoxyglucose F18); 9PHQ9Y1OLM (Prednisolone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170322
[St] Status:MEDLINE
[do] DOI:10.1007/s00256-017-2618-5


  8 / 2278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28293635
[Au] Autor:Suzuki T; Yoshida R; Okamoto A; Seri Y
[Ad] Endereço:Division of Allergy and Rheumatology, Japanese Red Cross Medical Center, Tokyo, Japan; Division of Rheumatology, Mitsui Memorial Hospital, Tokyo, Japan.
[Ti] Título:Semiquantitative Evaluation of Extrasynovial Soft Tissue Inflammation in the Shoulders of Patients with Polymyalgia Rheumatica and Elderly-Onset Rheumatoid Arthritis by Power Doppler Ultrasound.
[So] Source:Biomed Res Int;2017:4272560, 2017.
[Is] ISSN:2314-6141
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:. To develop a scoring system for evaluating the extrasynovial soft tissue inflammation of the shoulders in patients with polymyalgia rheumatica (PMR) and elderly-onset rheumatoid arthritis with PMR-like onset (pm-EORA) using ultrasound. . We analyzed stored power Doppler (PD) images obtained by the pretreatment examination of 15 PMR patients and 15 pm-EORA patients. A semiquantitative scoring system for evaluating the severity of PD signals adjacent to the anterior aspect of the subscapularis tendon was designed. . A four-point scale scoring for the hyperemia on the subscapularis tendon was proposed as follows in brief: 0 = absent or minimal flow, 1 = single vessel dots or short linear-shape signals, 2 = long linear-shape signals or short zone-shape signals, or 3 = long zone-shape signals. This scoring system showed good intra- and interobserver reliability and good correlation to quantitative pixel-counting evaluation. By using it, we demonstrated that inflammation in PMR is dominantly localized in extrasynovial soft tissue as compared with pm-EORA. . We proposed a reliable semiquantitative scoring system using ultrasound for the evaluation of extrasynovial soft tissue inflammation of the shoulders in patients with both PMR and pm-EORA. This system is simple to use and can be utilized in future investigations.
[Mh] Termos MeSH primário: Artrite Reumatoide/diagnóstico por imagem
Polimialgia Reumática/diagnóstico por imagem
Ombro/diagnóstico por imagem
Ultrassonografia Doppler
[Mh] Termos MeSH secundário: Idoso
Artrite Reumatoide/patologia
Feminino
Seres Humanos
Hiperemia/patologia
Inflamação
Masculino
Meia-Idade
Polimialgia Reumática/patologia
Reprodutibilidade dos Testes
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1155/2017/4272560


  9 / 2278 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28276953
[Au] Autor:Ji J; Dimitrijevic I; Sundquist J; Sundquist K; Zöller B
[Ad] Endereço:a Centre for Primary Health Care Research , Lund University/Region Skåne , Malmö , Sweden.
[Ti] Título:Risk of ocular manifestations in patients with giant cell arteritis: a nationwide study in Sweden.
[So] Source:Scand J Rheumatol;46(6):484-489, 2017 Nov.
[Is] ISSN:1502-7732
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: No large-scale nationwide study has determined the risk of ocular manifestations in patients with giant cell arteritis (GCA). The aim was to study the incidence and risk factors of ocular manifestations in patients with GCA in Sweden. METHOD: A national cohort was created by linking Swedish nationwide registers. GCA patients were identified from the Swedish Hospital Inpatient and Outpatient Registers between 2002 and 2010, and were followed until the development of ocular manifestations. Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated for ocular manifestations in patients with GCA compared to those without GCA. RESULTS: We identified 3737 males and 8311 females with GCA. A total of 1618 individuals had subsequent ocular manifestations, representing 13.4% of the GCA patients. The overall SIR of ocular manifestations was 6.96 (95% CI 6.63-7.31). The risk for disorders of the optic nerve or visual tract was particularly high (SIR = 51.68, 95% CI 46.12-57.73). Men with GCA had a higher risk than women, and GCA patients without polymyalgia rheumatica (PMR) symptoms had a higher risk than those with PMR symptoms. Living outside big cities was negatively associated with ocular manifestations in GCA patients, whereas hypertension and diabetes were associated with an increased risk of ocular manifestations. CONCLUSION: The overall risk of ocular manifestations was higher in GCA patients than in the general population, especially for men and for those without PMR symptoms.
[Mh] Termos MeSH primário: Oftalmopatias/epidemiologia
Arterite de Células Gigantes/epidemiologia
Polimialgia Reumática/epidemiologia
[Mh] Termos MeSH secundário: Idoso
Amaurose Fugaz/epidemiologia
Cegueira/epidemiologia
Cidades
Estudos de Coortes
Diabetes Mellitus/epidemiologia
Diplopia/epidemiologia
Dor Ocular/epidemiologia
Feminino
Seres Humanos
Hipertensão/epidemiologia
Incidência
Masculino
Distribuição Espacial da População
Oclusão da Artéria Retiniana/epidemiologia
Oclusão da Veia Retiniana/epidemiologia
Fatores de Risco
Fatores Sexuais
Suécia
Baixa Visão/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171107
[Lr] Data última revisão:
171107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170310
[St] Status:MEDLINE
[do] DOI:10.1080/03009742.2016.1266030


  10 / 2278 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28169601
[Au] Autor:Tamborrini G; Bauer M
[Ad] Endereço:1 Ultraschall Zentrum Rheumatologie, Basel.
[Ti] Título:CME-Rheumatologie 10/Auflösung: Schulterschmerzen unter TNF-Hemmer-Therapie..
[So] Source:Praxis (Bern 1994);106(3):159-160, 2017 Feb.
[Is] ISSN:1661-8157
[Cp] País de publicação:Switzerland
[La] Idioma:ger
[Mh] Termos MeSH primário: Síndrome de Guillain-Barré/induzido quimicamente
Síndrome de Guillain-Barré/diagnóstico
Polimialgia Reumática/tratamento farmacológico
Dor de Ombro/tratamento farmacológico
Dor de Ombro/etiologia
Espondilite Anquilosante/tratamento farmacológico
Fator de Necrose Tumoral alfa/antagonistas & inibidores
[Mh] Termos MeSH secundário: Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Tumor Necrosis Factor-alpha)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE
[do] DOI:10.1024/1661-8157/a002578



página 1 de 228 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde